Skip to content

The superior study (phase IV) of NBP on the Treatment of High Risk Non-Disabling Ischemic Cerebrovascular Disease and Platelet Microparticle Changes

The superior study (phase IV) of NBP on the Treatment of High Risk Non-Disabling Ischemic Cerebrovascular Disease and Platelet Microparticle Changes

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-IPR-17012622
Enrollment
Unknown
Registered
2017-09-08
Start date
2017-10-01
Completion date
Unknown
Last updated
2017-09-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

High Risk Non-Disabling Ischemic Cerebrovascular Disease

Interventions

Two cohorts:take NBP versus without NBP

Sponsors

The affiliated Hospital of Guangdong Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. aged 18 to 75 years male and female; 2. Onset the stroke no more than 72 hours; 3. TIA patients that has a high risk of stroke (ABCD2 score on admission>=4) or minor stroke (admitted to hospital NIHSS<=3) and no thrombolytic therapy; 4. Obtained the signed the informed consent from patients or patients with legally authorized representatives.

Exclusion criteria

Exclusion criteria: 1) coma (NIHSS 1a awareness level item> 1 point of the patient); 2) moderate to severe stroke symptoms (NIHSS> 3 points); 3) pseudo-pulpal numbness with dysphagia; 4) craniocerebral CT findings of intracranial hemorrhagic disease: cerebral hemorrhage, ventricular hemorrhage, subarachnoid hemorrhage, subdural or epidural hematoma; 5) previous cerebral hemorrhage, subarachnoid hemorrhage, cerebral arteriovenous malformations or cerebral aneurysms, brain tumor history; 6) combined with severe heart, liver, kidney and other organs dysfunction; 7) pregnant or lactating women and pregnant throughout the trial period; 8) with mental symptoms unable to collaborate.

Design outcomes

Primary

MeasureTime frame
The total effective rate of treatment on day 90;

Secondary

MeasureTime frame
platelet microparticles level;The incidence of stroke;Congnitive ablilty;

Countries

China

Contacts

Public ContactHuiting Zhang

The affiliated Hospital of Guangdong Medical University

barbara3367723@126.com+86 13824843219

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026